Disease midification and Duration of omalizumab Treatment in patients with severe allergic asthma

Matthias Volkmar Kopp, J Schreiber, S Korn, C Taube, R Buhl

Research Areas and Centers

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{1addf2caa147462793386e0f7fb8c1ba,

title = "Disease midification and Duration of omalizumab Treatment in patients with severe allergic asthma",

author = "Kopp, {Matthias Volkmar} and J Schreiber and S Korn and C Taube and R Buhl",

year = "2014",

month = mar,

language = "English",

volume = "2014",

journal = "Pneumologie",

issn = "0934-8387",

}